Pravin is a deep-tech multi-domain entrepreneur whose ventures sit at the intersection of science, sustainability, and scale. As the founder of numerous pioneering companies, he has spent his career building future-forward enterprises that challenge convention and drive systemic change. Whether advancing assisted reproduction, revolutionising livestock genetics, furthering quantum cybersecurity, developing clean fusion energy, or unlocking the potential of cross-species organ transplants, he approaches each venture with the precision of a scientist and the audacity of a disruptor. He thrives in ambiguity, embraces risk, and sees India not just as a market, but as a launchpad for global impact.

Aluri has mamy decades of experience as a business leader and investor having held prestigious positions as director of investments at ICICI Ventures and Managing Director of Private Equity at Morgan Stanley. Since then he turned his focus to deep-tech by founding revolutionary quantum cybersecurity and livestock genetics companies. Leveraging financial regulations and strategic acumen, he has built partnerships that amplify impact on global challenges, echoing his commitment to leadership and transformative change.

Simon is a World Economic Forum “Global Leader of Tomorrow” and experienced Angel, Venture Capital and Private Equity investor. Currently Chairman of MiAlgae and an Investor-Director of Roslin Technologies – the leading provider of pluripotent starter-cell lines for the production of cultured meat. Previous Chairman of ICRISAT in Hyderabad and founding CEO of Roslin BioMed which he spun out of the Roslin Institute in 1998 to commercialize the Nuclear Transfer cloning platform which enabled “Dolly the Sheep” and the University of Edinburgh’s Centre for Regenerative Medicine. Founding Investor in Tropical Animal Genetics and Jiva Sciences. Previous Vice-Chair of the US Biotechnology Industry Organization (BIO), Chair of BIO’s Bioethics Committee and the UK Biotechnology Industry Assocation (BIA).

Neeladri is a biotechnology scientist with 10 years’ experience spanning regenerative medicine, agritech, and medical-device innovation. At Nuvedo Labs he directs R&D for medicinal mushroom ingredients, engineering a streamlined extraction workflows and novel product formats bringing biotechnological principles to the wellness space. During his time at C-CAMP he helped create a droplet-microfluidic, single-cell analysis platform (OptiDrop) for multiplexed analysis and sorting of biological samples. He also developed a novel biopesticide from a soil microbe, developing semi-automated high throughput screening workflows, fermentation process scale-up and performing biomolecular characterisation, the technology has now been licensed to an agritech giant for commercialisation. At Prana he hopes to leverage his decade long inter-disciplinary experience working across different areas of biotech to lead the development of Xenotransplantation in India.

Dr Swaminathan is the Inaugural Chair of the Department of Nephrology and Endowed Chair Professor in the Indian Institute of Science and Tata-IISc Medical School. He serves as an adjunct faculty and research collaborator at the Mayo Clinic Arizona. His research interests are in the pathophysiology of kidney diseases, and discovery of novel therapeutic approaches to prevent and treat kidney diseases. His laboratory is broadly interested in fundamental studies in the pathophysiology of kidney diseases with a particular interest in examining the role of systemic and cellular iron metabolism in cell injury, proliferation, repair, and transformation. His current research focus is to develop novel disease models combined with translational studies to better understand acute and chronic kidney injury and to discover novel therapeutic approaches to reduce the burden of kidney disease. He is spearheading the xenotransplantation program at the IISc Medical School to establish India’s first Xenotransplantation surgery.

Strategic R&D leader and accomplished molecular biologist with over 15 years of experience spanning translational research across stem cell & regenerative medicine, reproductive biotechnology, molecular parasitology, and infectious diseases. She currently heads the Translational R&D Division at Tropical Animal Genetics (P) Ltd. She is widely recognized for mentoring multidisciplinary teams and leading high-impact research programs that bridge fundamental science with clinical and agricultural applications. Her expertise includes product development, IP portfolio management & regulatory compliance. She has served as Principal Investigator on several grant-funded projects, including those supported by the Bill & Melinda Gates Foundation and BIRAC, focusing on bovine and porcine stem-cell-derived embryo models. Her work is advancing the development of scalable platforms for in vitro gametogenesis, embryo characterization, and maternal-fetal crosstalk using 3D vascularized endometrial models.

Stem Cell Biologist with over 15 years of research experience in embryonic (ESC) and mesenchymal stem cell (MSC) biology, tissue engineering, and regenerative medicine. Proven expertise in isolating MSCs from diverse sources, characterizing and differentiating stem cells, and developing analytical methods for stem cell-based therapeutics. Contributed to pre-clinical studies on stem cell applications in diabetes management and clinical-grade delivery systems. Currently serving as Principal Scientist at Tropical Animal Genetics, leading projects on bovine embryonic stem cell line development, characterization, and differentiation into oocytes and iblastoids. Committed to advancing precision medicine and applied biotechnology through innovative stem cell research.

Dr. Shweta Sharma is a biotechnology researcher with specialized expertise in cell signaling, stem cell biology, and molecular techniques. Her doctoral research investigated the regulatory roles of calcium signaling, endoplasmic reticulum (ER) stress, and autophagy in maintaining cellular homeostasis, with a focus on their contributions to neuromuscular disorders. In addition to this she has explored metabolic engineering and lipid biology, examining effect of nutrient conditions and stress responses on lipid and cholesterol regulation in mammalian cell culture system. Currently, she is engaged in stem-cell-based embryo model research, concentrating on the generation and characterization of bovine blastoids to advance applications in regenerative and reproductive biology.

E Pranshu Rao is a biotechnology researcher with deep expertise in regenerative medicine, cell culture, and biomaterials. His work focuses on the development of cell-based therapies, including adipose-derived stromal vascular fraction (ADSVF) for osteoarthritis and corneal grafts, conducted in cGMP-compliant environments. He has also led advanced research in bovine embryonic stem cell biology, optimizing blastocyst development and investigating pluripotency mechanisms. His technical competencies span molecular biology, epigenetics, biomaterial fabrication, proteomics, and in vivo experimentation. His interdisciplinary approach bridges fundamental research with translational and clinical applications, advancing the frontiers of regenerative biotechnology.